This article highlights recent pioneering work by Günther et al. towards the discovery of potential repurposed antiviral compounds (peptidomimetic and non-peptidic) against the SARS-CoV-2 main protease (Mpro ). The antiviral activity of the most potent drugs is discussed along with their binding mode to Mpro as observed through X-ray crystallographic screening.
Keywords: SARS-CoV-2; X-ray crystallographic screening; allosteric inhibitors; antiviral drugs; drug screening.
© 2021 Wiley-VCH GmbH.